Compare MFIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2004 | 2019 |
| Metric | MFIC | PHAT |
|---|---|---|
| Price | $10.90 | $13.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $12.63 | ★ $17.33 |
| AVG Volume (30 Days) | 604.7K | ★ 1.3M |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | ★ 13.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $324,678,000.00 | $147,190,000.00 |
| Revenue This Year | $9.08 | $221.76 |
| Revenue Next Year | N/A | $81.67 |
| P/E Ratio | $10.37 | ★ N/A |
| Revenue Growth | 11.35 | ★ 460.30 |
| 52 Week Low | $10.18 | $2.21 |
| 52 Week High | $14.74 | $18.31 |
| Indicator | MFIC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 43.26 |
| Support Level | $11.10 | $13.14 |
| Resistance Level | $11.25 | $14.31 |
| Average True Range (ATR) | 0.23 | 0.82 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 8.96 | 23.53 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.